
Game-Changer in Cancer Therapy: AstraZeneca Bets Big on Innovative Cell Therapies with $1 Billion Acquisition
AstraZeneca acquires EsoBiotec to revolutionize cancer therapy with groundbreaking ENaBL technology. The acquisition, valued at up to $1 billion, promises rapid deployment of cell therapies, turning complex treatments into quick IV injections. ENaBL technology enables T cells to efficiently target and destroy